The successful use of electroconvulsive therapy in a patient with interferon-induced psychotic depression

Journal of ECT

Volumn 23, Issue 4, 2007, Pages 291-292

  Zincke, Miriam Tanja ^a   Kurani, Amit ^a   Istafanous, Rafik ^a   Kellner, Charles ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

ECT; HCV; Pegylated interferon alfa 2b

Indexed keywords

BENZATROPINE; CLONAZEPAM; METHADONE; MIRTAZAPINE; PEGINTERFERON ALPHA2B; QUETIAPINE; RISPERIDONE; SERTRALINE;

ADULT; ANAMNESIS; ARTICLE; AUDITORY HALLUCINATION; BEDTIME DOSAGE; CASE REPORT; CLINICAL FEATURE; DAILY LIFE ACTIVITY; DEPRESSION; DEPRESSIVE PSYCHOSIS; DISEASE SEVERITY; DRUG ABUSE; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FEMALE; HEPATITIS C; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MEDICAL LITERATURE; MENTAL HEALTH; MORNING DOSAGE; SEIZURE; SUICIDAL IDEATION; VISUAL HALLUCINATION;

ANTIVIRAL AGENTS; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAPHY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MIDDLE AGED; PSYCHOSES, SUBSTANCE-INDUCED; RETREATMENT; TREATMENT OUTCOME;

EID: 37349125945     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0b013e3181492224     Document Type: Article

References (13)

1. Asnis G, De la Garza R. Interferon induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol. 2006;40:322-335.
2. Crone C, Gabriel G. Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. J Psychiatr Pract. 2003;9:93-110.
3. Rifai M, Indest D, Loftis J, et al. Psychiatric management of the hepatitis C patient. Curr Treat Options Gastroenterol. 2006;9:508-519.
4. Aspinall R, Pockros P. Review article: the management of side-effects during therapy for hepatitis C. Aliment Pharmacol Ther. 2004;20:917-929.
5. Horsmans Y. Chronic hepatitis C, depression and interferon. J Hepatol. 2005;42:788-789.
6. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24:38-47.
7. Prior T, Chue P. Psychotic depression occurring after stopping interferon-alpha. J Clin Psychopharmacol. 1999;19:385-386.
8. Okereke O. Neuropsychiatric complications associated with interferon-alpha-2b treatment of malignant melanoma. Psychosomatics. 2002;43:237-240.
9. Raison C, Demetrashvili M, Capuron L, et al. Neuropsychiatric adverse effects of interferon-alpha. Recognition and management. CNS Drugs. 2005;19:105-123.
10. Asnis G, De La Garza R. Interferon-induced depression: strategies in treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:808-818.
11. Capuron L, Ravaud A. Prediction of the depressive effects of interferon alpha therapy by the patient's initial affective state. N Engl J Med. 1999;340:1370.
12. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2000;7:942-947.
13. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon-alpha. N Engl J Med. 2001;344:961-966.